{
    "data": [
        {
            "id": "1919061",
            "type": "article",
            "attributes": {
                "publishOn": "2013-12-28T03:06:05-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Short-Term Expected Gross Margin Contraction Fails To Change Bullish Outlook On CVS",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39231",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "126901",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1919061-short-term-expected-gross-margin-contraction-fails-to-change-bullish-outlook-on-cvs"
            }
        },
        {
            "id": "1916081",
            "type": "article",
            "attributes": {
                "publishOn": "2013-12-25T10:17:37-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS Caremark - Strong Outlook And Increased Payouts Trigger Enthusiasm Among Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1916081-cvs-caremark-strong-outlook-and-increased-payouts-trigger-enthusiasm-among-investors"
            }
        },
        {
            "id": "1880281",
            "type": "article",
            "attributes": {
                "publishOn": "2013-12-05T12:37:21-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS Caremark: Enhancing Its Revenue Streams",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "57561",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "125765",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1880281-cvs-caremark-enhancing-its-revenue-streams"
            }
        },
        {
            "id": "1868681",
            "type": "article",
            "attributes": {
                "publishOn": "2013-11-29T10:39:02-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "As CVS Caremark Acquires Coram From Apria Healthcare, Here's Why I'm Staying Long",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41381",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "125474",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1868681-as-cvs-caremark-acquires-coram-from-apria-healthcare-heres-why-im-staying-long"
            }
        },
        {
            "id": "1867681",
            "type": "article",
            "attributes": {
                "publishOn": "2013-11-28T06:07:19-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS Caremark - Little Appeal Despite A Nice Strategic Addition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1867681-cvs-caremark-little-appeal-despite-a-nice-strategic-addition"
            }
        },
        {
            "id": "1866011",
            "type": "article",
            "attributes": {
                "publishOn": "2013-11-27T09:40:26-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ModernGraham Valuation Of CVS Caremark",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23471",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "125384",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1866011-moderngraham-valuation-of-cvs-caremark"
            }
        },
        {
            "id": "1742942",
            "type": "article",
            "attributes": {
                "publishOn": "2013-10-14T03:59:24-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS: 120%+ Returns Have Made This Drug Retailer Overvalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53422",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1742942-cvs-120-percent-returns-have-made-this-drug-retailer-overvalued"
            }
        },
        {
            "id": "1741582",
            "type": "article",
            "attributes": {
                "publishOn": "2013-10-11T16:26:17-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What CVS Bulls Can Expect From Here?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "38201",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "123164",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1741582-what-cvs-bulls-can-expect-from-here"
            }
        },
        {
            "id": "1739122",
            "type": "article",
            "attributes": {
                "publishOn": "2013-10-10T13:27:51-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Undervalued Stock Of The Week: CVS Caremark",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25218",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1739122-undervalued-stock-of-the-week-cvs-caremark"
            }
        },
        {
            "id": "1717072",
            "type": "article",
            "attributes": {
                "publishOn": "2013-09-27T10:19:35-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Flu Season Remains A Growing Asset For Pharmacies",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "54812",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1717072-flu-season-remains-a-growing-asset-for-pharmacies"
            }
        },
        {
            "id": "1716042",
            "type": "article",
            "attributes": {
                "publishOn": "2013-09-26T17:21:07-04:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What's The Correct Discount Rate To Use? Part 2B",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23179",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1716042-whats-the-correct-discount-rate-to-use-part-2b"
            }
        },
        {
            "id": "1708762",
            "type": "article",
            "attributes": {
                "publishOn": "2013-09-23T14:07:22-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS Caremark: An Upside Potential In Excess Of Downside Risk",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "54532",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "122258",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1708762-cvs-caremark-an-upside-potential-in-excess-of-downside-risk"
            }
        },
        {
            "id": "1645652",
            "type": "article",
            "attributes": {
                "publishOn": "2013-08-20T03:07:54-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS: An Undervalued Prescription For Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "52422",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "120478",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1645652-cvs-an-undervalued-prescription-for-growth"
            }
        },
        {
            "id": "1605742",
            "type": "article",
            "attributes": {
                "publishOn": "2013-08-05T19:28:43-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS Earnings: Generic And Private Label Drugs Can Slow Growth But Lift Margins",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23479",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1605742-cvs-earnings-generic-and-private-label-drugs-can-slow-growth-but-lift-margins"
            }
        },
        {
            "id": "1470501",
            "type": "article",
            "attributes": {
                "publishOn": "2013-05-30T11:30:13-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS Has A Bright Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "42371",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "116576",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1470501-cvs-has-a-bright-future"
            }
        },
        {
            "id": "1464561",
            "type": "article",
            "attributes": {
                "publishOn": "2013-05-28T12:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS Vs. Walgreen - Who You Got?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "45851",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1464561-cvs-vs-walgreen-who-you-got"
            }
        },
        {
            "id": "1406181",
            "type": "article",
            "attributes": {
                "publishOn": "2013-05-06T14:14:30-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Generic Drugs Boost CVS Caremark's Earnings, $57 Fair Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23479",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1406181-generic-drugs-boost-cvs-caremarks-earnings-57-fair-value"
            }
        },
        {
            "id": "1403731",
            "type": "article",
            "attributes": {
                "publishOn": "2013-05-05T13:57:43-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS Caremark: Earnings Up, Valuation Up Even More, But The Stock Remains Attractive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "115464",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1403731-cvs-caremark-earnings-up-valuation-up-even-more-but-the-stock-remains-attractive"
            }
        },
        {
            "id": "1384871",
            "type": "article",
            "attributes": {
                "publishOn": "2013-04-30T13:21:26-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS Caremark Earnings Preview: Generics And Front-Store Sales Can Lift Margins",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23479",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1384871-cvs-caremark-earnings-preview-generics-and-front-store-sales-can-lift-margins"
            }
        },
        {
            "id": "1328231",
            "type": "article",
            "attributes": {
                "publishOn": "2013-04-08T16:55:23-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why We Like CVS Caremark",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41941",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1328231-why-we-like-cvs-caremark"
            }
        },
        {
            "id": "1273991",
            "type": "article",
            "attributes": {
                "publishOn": "2013-03-14T12:01:26-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS Caremark: Reasons To Support A Buy At The High",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "30811",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "113106",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1273991-cvs-caremark-reasons-to-support-a-buy-at-the-high"
            }
        },
        {
            "id": "1205631",
            "type": "article",
            "attributes": {
                "publishOn": "2013-02-20T06:06:04-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Closer Look At CVS's Retail Clinic Business: MinuteClinic",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23479",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1205631-a-closer-look-at-cvss-retail-clinic-business-minuteclinic"
            }
        },
        {
            "id": "1180991",
            "type": "article",
            "attributes": {
                "publishOn": "2013-02-13T14:49:17-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS Caremark: An Investor-Friendly Free Cash Flow Generator With Strong Growth Potential",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "111786",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1180991-cvs-caremark-an-investor-friendly-free-cash-flow-generator-with-strong-growth-potential"
            }
        },
        {
            "id": "1156731",
            "type": "article",
            "attributes": {
                "publishOn": "2013-02-05T09:05:31-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS Earnings Preview: The Upside Catalysts Are Fading",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1156731-cvs-earnings-preview-the-upside-catalysts-are-fading"
            }
        },
        {
            "id": "1154961",
            "type": "article",
            "attributes": {
                "publishOn": "2013-02-04T14:50:13-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Watching For Flu, Express Scripts Impacts CVS Caremark's Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23479",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1154961-watching-for-flu-express-scripts-impacts-cvs-caremarks-earnings"
            }
        },
        {
            "id": "1126731",
            "type": "article",
            "attributes": {
                "publishOn": "2013-01-23T06:13:10-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Into CVS's Triple Play - Capital Gains, Dividend Yield And Income Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "37511",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "110820",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1126731-buy-into-cvss-triple-play-capital-gains-dividend-yield-and-income-growth"
            }
        },
        {
            "id": "1101341",
            "type": "article",
            "attributes": {
                "publishOn": "2013-01-08T17:38:56-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "CVS Caremark's Dividend Increase And The Facts Behind It",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1212",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1101341-cvs-caremarks-dividend-increase-and-the-facts-behind-it"
            }
        }
    ]
}